Tetralogic Pharmaceuticals Corp (TLOG) 4.57 $TLOG
Can the Rally in TetraLogic (TLOG) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:15AM CDT
Can the Rally in TetraLogic (TLOG) Shares Continue?
TetraLogic Announces Closing of $47 Million Convertible Senior Notes Offering
GlobeNewswire - Tue Jun 24, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) (the "Company" ) announced the closing of its previously-announced offering of $47 million aggregate principal amount of its 8% Convertible Senior Notes due 2019 (the "Notes"
in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" .
TetraLogic prices offering of USD47m convertible notes
M2 - Wed Jun 18, 3:37AM CDT
Biopharmaceutical company TetraLogic Pharmaceuticals (NasdaqGM:TLOG) said on Tuesday that it has priced USD47m in aggregate principal amount of its 8% convertible senior notes due 2019 in a private offering that is expected to close on 23 June 2014.
TetraLogic Announces Pricing of $47 Million Offering of Convertible Notes
GlobeNewswire - Tue Jun 17, 8:05PM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) (the "Company" announced the pricing of its offering of $47 million in aggregate principal amount of its 8% Convertible Senior Notes due 2019 (the "Notes" in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" .
TetraLogic Pharmaceuticals Announces Conference Call With Dr. Marc Pellegrini of the Walter and Eliza Hall Institute of Medical Research to Discuss TetraLogic Infectious Disease Program
GlobeNewswire - Fri Jun 13, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) ("Company" today announced that it will host a conference call and live audio webcast on Monday, June 16, 2014 at 08:00 a.m. Eastern Time with Dr. Marc Pellegrini, Laboratory Head, Infection and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. Dr. Pellegrini will review preclinical studies indicating the potential for broad applicability of TetraLogic's lead compound, birinapant, in models of infectious disease, including Hepatitis B. The Company will also discuss future planned clinical activities, including a Phase 1 clinical trial of birinapant in patients with chronic Hepatitis B infection, which the Company intends to commence in late 2014 and for which Dr. Pellegrini will play a key leadership role.
TetraLogic Pharmaceuticals Announces Preclinical Data Indicating Birinapant's Breadth of Activity in Models of Infectious Disease
GlobeNewswire - Mon Jun 09, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced results from its collaboration with the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, indicating that SMAC mimetics, including TetraLogic's lead compound birinapant, may have broad applicability in the treatment of infectious disease.
TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual American Society of Clinical Oncology Meeting
GlobeNewswire - Wed May 28, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the phase 1 randomized placebo controlled clinical study of SHAPE (SHP 141) in Stage IA -IIA Cutaneous T Cell Lymphoma will be presented at the American Society of Clinical Oncology meeting to be held in Chicago from May 30- June 3, 2014.
TetraLogic Pharmaceuticals Announces Selection of Phase 2 Dose for Randomized Clinical Study of Birinapant in Combination With Azacitidine in Naive Patients With Higher Risk Myelodysplastic Syndromes (MDS)
GlobeNewswire - Tue May 27, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that, based upon data from its Phase 1b study of birinapant in combination with azacitidine in patients with relapsed/refractory or naïve higher risk MDS, it selected a dose of 13mg/m twice weekly for three weeks out of four to be used in its Phase 2 clinical trial. The primary objective of the Phase 1b clinical study is to characterize the safety and tolerability and determine the recommended phase 2 dose of birinapant when administered in combination with azacitidine. Additional objectives of the study are to assess any preliminary indications of efficacy and pharmacodynamics of the combination.
TetraLogic Pharmaceuticals (TLOG) Soars: Stock Up 20.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 8:39AM CDT
TetraLogic Pharmaceuticals Corporation was a big mover last session, as its shares rose almost 21% on the day.
TetraLogic Pharmaceuticals Announces Publication of Preclinical Characterization of Birinapant
GlobeNewswire - Tue Apr 01, 6:03AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in the April issue of Molecular Cancer Therapeutics further advances the preclinical characterization of its lead SMAC-Mimetic birinapant, which is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors.
TetraLogic to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Mar 31, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 10:40 a.m. Eastern Time in New York, NY. Mr. Buchi will provide an overview of the Company and its corporate activities.
TetraLogic Pharmaceuticals to Present Data From Its SMAC-Mimetic Program at Upcoming AACR Annual Meeting 2014
GlobeNewswire - Thu Mar 27, 3:12PM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from its novel SMAC-Mimetic program will be presented during presentations at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-9, 2014 at the San Diego Convention Center in San Diego, California.
J. Kevin Buchi, President and Chief Executive Officer, Awarded the Pennsylvania Bio's Frank Baldino Bioscience CEO of the Year
GlobeNewswire - Thu Mar 13, 8:01AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, is the recipient of the 2014 Frank Baldino Jr. CEO of the Year Award awarded by Pennsylvania Bio, the statewide life sciences industry trade association. Mr. Buchi was honored at PA Bio's Annual Dinner and Awards Celebration and Ceremony on March 12, 2014 in Philadelphia.
TetraLogic to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the Cowen and Company 34 Annual Health Care Conference on Wednesday, March 5, 2014 at 8:40 a.m. Eastern Time in Boston, MA. Mr. Buchi will provide an overview of the Company and its corporate activities.
Over 25 Companies to Present at Emerald Groundhog Investment Forum: Thursday, February 6th
Business Wire - Tue Feb 04, 3:12PM CST
Pennsylvania's famous groundhog Punxsutawney Phil may have forecast six more weeks of winter, but he's delivering clear skies and a perfect day for the Groundhog Day Investment Forum on Thursday, February 6th. Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the Radisson Warwick Hotel in Philadelphia, PA for the 21st annual event. This year's Forum will include sessions focusing on cyber security, the robotics revolution, local and regional banks, fixed income securities and alternatives and ongoing innovations by corporate America generating potential investment opportunities.
Investment Industry to Gather in Philadelphia at 21st Annual Groundhog Investment Forum
Business Wire - Thu Jan 30, 1:00PM CST
Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the 21st annual Emerald Groundhog Day Investment Forum, scheduled to be held on Thursday, February 6th at the Radisson Warwick Hotel in Philadelphia, PA. "We say that the 2014 investment year begins in earnest with our annual Forum," said Emerald CEO and Founder Joseph E. Besecker. "Public company senior managers, investment portfolio managers and research analysts come together to review 2013 and provide their initial outlook to 2014 and beyond." This year's Forum will include sessions focusing on cyber security, the robotics revolution, local and regional banks, fixed income securities and alternatives and ongoing innovations by corporate America generating potential investment opportunities.
TetraLogic Announces Licensing and Research Collaboration With Walter and Eliza Hall Institute of Medical Research
GlobeNewswire - Tue Jan 21, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has entered into a research collaboration with the Walter and Eliza Hall Institute of Medical Research to examine TetraLogic's SMAC-Mimetic birinapant in viral infections. Preclinical studies performed at the WEHI have indicated that SMAC-Mimetics decrease the viral burden in mice with human Hepatitis B Virus (HBV) by inducing apoptosis of virally infected hepatocytes while sparing the non-infected cells.
TetraLogic Announces Exercise of Over-Allotment Option
GlobeNewswire - Tue Dec 31, 3:05PM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that the underwriters for its initial public offering of common stock have exercised their option to purchase an additional 1,072,115 shares of common stock at a public offering price of $7.00 per share, before the underwriting discount. The closing of the option exercise occurred on December 31, 2013, resulting in net proceeds to TetraLogic of approximately $6,970,000 after the underwriting discount and offering costs.
Nasdaq stocks posting largest percentage increases
AP - Mon Dec 30, 4:59PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TetraLogic Pharmaceuticals Corporation [TLOG] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Wed Dec 18, 9:00AM CST
What:
Can the Rally in TetraLogic (TLOG) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:15AM CDT
Can the Rally in TetraLogic (TLOG) Shares Continue?
TetraLogic Announces Closing of $47 Million Convertible Senior Notes Offering
GlobeNewswire - Tue Jun 24, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) (the "Company" ) announced the closing of its previously-announced offering of $47 million aggregate principal amount of its 8% Convertible Senior Notes due 2019 (the "Notes"
in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" . TetraLogic prices offering of USD47m convertible notes
M2 - Wed Jun 18, 3:37AM CDT
Biopharmaceutical company TetraLogic Pharmaceuticals (NasdaqGM:TLOG) said on Tuesday that it has priced USD47m in aggregate principal amount of its 8% convertible senior notes due 2019 in a private offering that is expected to close on 23 June 2014.
TetraLogic Announces Pricing of $47 Million Offering of Convertible Notes
GlobeNewswire - Tue Jun 17, 8:05PM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) (the "Company"
announced the pricing of its offering of $47 million in aggregate principal amount of its 8% Convertible Senior Notes due 2019 (the "Notes" in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" . TetraLogic Pharmaceuticals Announces Conference Call With Dr. Marc Pellegrini of the Walter and Eliza Hall Institute of Medical Research to Discuss TetraLogic Infectious Disease Program
GlobeNewswire - Fri Jun 13, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) ("Company"
today announced that it will host a conference call and live audio webcast on Monday, June 16, 2014 at 08:00 a.m. Eastern Time with Dr. Marc Pellegrini, Laboratory Head, Infection and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. Dr. Pellegrini will review preclinical studies indicating the potential for broad applicability of TetraLogic's lead compound, birinapant, in models of infectious disease, including Hepatitis B. The Company will also discuss future planned clinical activities, including a Phase 1 clinical trial of birinapant in patients with chronic Hepatitis B infection, which the Company intends to commence in late 2014 and for which Dr. Pellegrini will play a key leadership role. TetraLogic Pharmaceuticals Announces Preclinical Data Indicating Birinapant's Breadth of Activity in Models of Infectious Disease
GlobeNewswire - Mon Jun 09, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced results from its collaboration with the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, indicating that SMAC mimetics, including TetraLogic's lead compound birinapant, may have broad applicability in the treatment of infectious disease.
TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual American Society of Clinical Oncology Meeting
GlobeNewswire - Wed May 28, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the phase 1 randomized placebo controlled clinical study of SHAPE (SHP 141) in Stage IA -IIA Cutaneous T Cell Lymphoma will be presented at the American Society of Clinical Oncology meeting to be held in Chicago from May 30- June 3, 2014.
TetraLogic Pharmaceuticals Announces Selection of Phase 2 Dose for Randomized Clinical Study of Birinapant in Combination With Azacitidine in Naive Patients With Higher Risk Myelodysplastic Syndromes (MDS)
GlobeNewswire - Tue May 27, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that, based upon data from its Phase 1b study of birinapant in combination with azacitidine in patients with relapsed/refractory or naïve higher risk MDS, it selected a dose of 13mg/m twice weekly for three weeks out of four to be used in its Phase 2 clinical trial. The primary objective of the Phase 1b clinical study is to characterize the safety and tolerability and determine the recommended phase 2 dose of birinapant when administered in combination with azacitidine. Additional objectives of the study are to assess any preliminary indications of efficacy and pharmacodynamics of the combination.
TetraLogic Pharmaceuticals (TLOG) Soars: Stock Up 20.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 8:39AM CDT
TetraLogic Pharmaceuticals Corporation was a big mover last session, as its shares rose almost 21% on the day.
TetraLogic Pharmaceuticals Announces Publication of Preclinical Characterization of Birinapant
GlobeNewswire - Tue Apr 01, 6:03AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in the April issue of Molecular Cancer Therapeutics further advances the preclinical characterization of its lead SMAC-Mimetic birinapant, which is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors.
TetraLogic to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Mar 31, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 10:40 a.m. Eastern Time in New York, NY. Mr. Buchi will provide an overview of the Company and its corporate activities.
TetraLogic Pharmaceuticals to Present Data From Its SMAC-Mimetic Program at Upcoming AACR Annual Meeting 2014
GlobeNewswire - Thu Mar 27, 3:12PM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from its novel SMAC-Mimetic program will be presented during presentations at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-9, 2014 at the San Diego Convention Center in San Diego, California.
J. Kevin Buchi, President and Chief Executive Officer, Awarded the Pennsylvania Bio's Frank Baldino Bioscience CEO of the Year
GlobeNewswire - Thu Mar 13, 8:01AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, is the recipient of the 2014 Frank Baldino Jr. CEO of the Year Award awarded by Pennsylvania Bio, the statewide life sciences industry trade association. Mr. Buchi was honored at PA Bio's Annual Dinner and Awards Celebration and Ceremony on March 12, 2014 in Philadelphia.
TetraLogic to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the Cowen and Company 34 Annual Health Care Conference on Wednesday, March 5, 2014 at 8:40 a.m. Eastern Time in Boston, MA. Mr. Buchi will provide an overview of the Company and its corporate activities.
Over 25 Companies to Present at Emerald Groundhog Investment Forum: Thursday, February 6th
Business Wire - Tue Feb 04, 3:12PM CST
Pennsylvania's famous groundhog Punxsutawney Phil may have forecast six more weeks of winter, but he's delivering clear skies and a perfect day for the Groundhog Day Investment Forum on Thursday, February 6th. Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the Radisson Warwick Hotel in Philadelphia, PA for the 21st annual event. This year's Forum will include sessions focusing on cyber security, the robotics revolution, local and regional banks, fixed income securities and alternatives and ongoing innovations by corporate America generating potential investment opportunities.
Investment Industry to Gather in Philadelphia at 21st Annual Groundhog Investment Forum
Business Wire - Thu Jan 30, 1:00PM CST
Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the 21st annual Emerald Groundhog Day Investment Forum, scheduled to be held on Thursday, February 6th at the Radisson Warwick Hotel in Philadelphia, PA. "We say that the 2014 investment year begins in earnest with our annual Forum," said Emerald CEO and Founder Joseph E. Besecker. "Public company senior managers, investment portfolio managers and research analysts come together to review 2013 and provide their initial outlook to 2014 and beyond." This year's Forum will include sessions focusing on cyber security, the robotics revolution, local and regional banks, fixed income securities and alternatives and ongoing innovations by corporate America generating potential investment opportunities.
TetraLogic Announces Licensing and Research Collaboration With Walter and Eliza Hall Institute of Medical Research
GlobeNewswire - Tue Jan 21, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has entered into a research collaboration with the Walter and Eliza Hall Institute of Medical Research to examine TetraLogic's SMAC-Mimetic birinapant in viral infections. Preclinical studies performed at the WEHI have indicated that SMAC-Mimetics decrease the viral burden in mice with human Hepatitis B Virus (HBV) by inducing apoptosis of virally infected hepatocytes while sparing the non-infected cells.
TetraLogic Announces Exercise of Over-Allotment Option
GlobeNewswire - Tue Dec 31, 3:05PM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that the underwriters for its initial public offering of common stock have exercised their option to purchase an additional 1,072,115 shares of common stock at a public offering price of $7.00 per share, before the underwriting discount. The closing of the option exercise occurred on December 31, 2013, resulting in net proceeds to TetraLogic of approximately $6,970,000 after the underwriting discount and offering costs.
Nasdaq stocks posting largest percentage increases
AP - Mon Dec 30, 4:59PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TetraLogic Pharmaceuticals Corporation [TLOG] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Wed Dec 18, 9:00AM CST
What:
